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 Background: Transplantation of liver grafts from deceased donors who experienced cardiac arrest prior to liver procurement 
is now common. This single-center study analyzed the impact of pre-donation arrest time on clinical outcomes 
in liver transplantation.
 Material/Methods: Records of all orthotopic liver transplants performed at a single center over a 15-year period were reviewed. 
Donor records were reviewed and total arrest time was calculated as cumulative minutes. Post-transplant liver 
graft function was assessed using laboratory values. Graft survival was assessed with Cox regression analysis.
 Results: Records for 1830 deceased donor transplants were reviewed, and 521 donors experienced pre-procurement 
cardiac arrest (28%). Median arrest time was 21 min (mean 25 min, range 1–120 min). After transplant, the 
peak alanine aminotransferase and bilirubin levels for liver grafts from donors with arrest were lower compared 
to those for donors without arrest (p<0.001). Early allograft dysfunction occurred in 25% (arrest) and 28% (no 
arrest) of patients (p=0.22). There were no differences in risk of early graft loss (3% vs. 3%, p=0.84), length of 
hospital stay (10 vs. 10 days, p=0.76), and 1-year graft survival (89% vs. 89%, p=0.94). Cox regression analysis 
comparing 4 groups (no arrest, <20 min, 20–40 min, and >40 min arrest) demonstrated no statistically signifi-
cant difference in survival at 10 years. Subgroup analysis of 93 donation after cardiac death grafts showed no 
significant difference for these same outcomes.
 Conclusions: These results support the use of select deceased liver donors who experience pre-donation cardiac arrest. 
Pre-donation arrest may be associated with less early allograft dysfunction, but had no impact on long-term 
clinical outcomes. The results for donation after cardiac death donors were similar.
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 Abbreviations: PPCA – pre-procurement cardiac arrest; DBD – donation after brain death; DCD – donation after cardiac 
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Background
The use of extended criteria organ donors is now common in 
liver transplantation [1,2]. Extended criteria for liver donation 
have never been defined because of the complexity of matching 
donors and recipients, and the number of interacting factors 
considered in the matching process. One factor that has not 
been fully studied is donor pre-procurement cardiac arrest 
(PPCA). Historically, some centers considered any uncontrolled 
donor PPCA as an exclusionary criterion for liver donation. Now, 
use of these donors is routine [3,4]. Previous clinical investi-
gation of PPCA assessed the presence of ischemic precondi-
tioning induced by the hypotension associated with the ar-
rest event [5–7]. Findings from these studies suggested similar 
clinical results for grafts from donors with PPCA. Subsequent 
studies supported these findings, although the study popu-
lations were small and did not represent a wide range of ar-
rest times [8–10].
Another line of investigation in this field involves electively 
inducing short periods of ischemia under controlled settings 
at the time of procurement in donors previously declared brain 
dead. In these reports, ischemia is induced by clamping the por-
tal vein and hepatic artery supplying the entire liver, or portion 
of liver being procured, for 5–10 min [11–18]. A meta-analysis 
of these small studies concluded that controlled ischemic pre-
conditioning resulted in reduced liver injury following trans-
plant and a large (but not statistically significant) reduction in 
1-year mortality [19]. The present study was designed to ana-
lyze the clinical impact of uncontrolled PPCA on early and late 
post-transplant outcomes in a large population of liver trans-
plant patients. Outcomes included early liver allograft func-
tion, and both early and late liver graft survival. Analysis in-
cluded stratification by calculated length of arrest time. Data 
are included for both donation after brain death (DBD) and 
donation after cardiac death (DCD) cases.
Material and Methods
The electronic medical records for all orthotopic liver trans-
plants performed at a single large U.S. center between 2001 
and 2015 were reviewed (n=1830). Data were extracted from 
the transplant recipient registry at our center, electronic med-
ical records, and donor information from the Indiana Donor 
Network (IDN). All liver transplant recipients were included as 
long as they were age 18 years and older and received a de-
ceased donor allograft. Liver graft and post-transplant patient 
survival data were collected from the database, which is up-
dated on a regular basis. This database also includes labora-
tory values measured for organ donors and in the first year 
post-transplant for all transplant recipients.
Donor PPCA time was calculated as the total of all documented 
arrest times prior to organ donation. This arrest time may have 
occurred in the field prior to hospital admission, or post-ad-
mission prior to stabilization for organ donation. The calcula-
tion of arrest time for patients found in asystole on first pre-
sentation started at the time cardiopulmonary resuscitation 
was initiated. Regarding resuscitation efforts, information 
about location, personnel, and quality of this care could not 
be reliably characterized from the available records. Therefore, 
resuscitation administered by by-standers, pre-hospital per-
sonnel, and hospital staff were considered equivalent for this 
study. All organ donors recovered from the arrest event and 
were stabilized prior to proceeding with organ procurement. 
Surgeon criteria for accepting and implanting individual liver 
grafts were not documented. Donor cause of death was cate-
gorized based upon a review of the donor records. Exclusionary 
criteria for deceased donor liver grafts are multifactorial, but 
generally include total steatosis greater than 50%, necrosis 
greater than 20%, severe vascular disease of the hepatic artery, 
non-repairable trauma, certain donor neoplasms, and warm 
ischemia time greater than 30 min for donation after cardiac 
death. Of course, these factors depend both on donor and re-
cipient age and other co-morbidities. The number of liver grafts 
rejected was not recorded, so the percentage of grafts trans-
planted could not be calculated.
All liver transplant recipients at this center were listed for trans-
plant according to standard criteria. For patients receiving re-
transplant within 30 days of the first transplant, the analysis 
included only data for the original transplant. Post-transplant 
liver graft function was assessed by the combination of liver 
function enzymes, international normalized ratio (INR), and 
early graft loss, as suggested by Olthoff et al. [20]. Specifically, 
early allograft dysfunction is defined as aspartate or alanine 
aminotransferase (AST, ALT) higher than 2000 u/L in the first 
7 days post-transplant, day 7 total bilirubin level greater than 
9.9, or day 7 international normalized ratio greater than 1.5. 
For the present study, serum ALT levels were used as a marker 
of liver injury because of its greater liver specificity when com-
pared to AST [21]. Some researchers have suggested that se-
rum ALT level on post-transplant day 3 is a better marker for 
liver ischemia injury than peak post-transplant ALT [22,23]. 
Both of these levels are reported in the present study. Any graft 
loss that occurred within 7 days of transplant was recorded as 
primary non-function as long as there was no clearly identi-
fiable etiology. All liver transplant recipients were included in 
the final analysis of data, without any exclusions.
The protocol for induction and maintenance immunosuppres-
sion at our center has been described. Induction included rabbit 
antithymocyte globulin and steroids, followed by maintenance 
with Prograf monotherapy [24]. Deceased donor liver allografts 
were procured using previously described techniques [25]. Our 
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center uses a large percentage of extended criteria donors, 
which has been described [1,2]. Our protocol for DCD pro-
curements has also been described [26]. Our center primarily 
uses a piggyback hepatectomy technique, which was used in 
95% of cases, with no use of portal-caval shunt [27]. Veno-
venous bypass was not used in any case. Use of an antifibri-
nolytic agent (aprotinin or aminocaproic acid) is routine [28].
Standard statistical testing was utilized for continuous and cate-
gorical variables, as indicated. A Cox proportional hazards model 
was constructed for survival analysis. Co-variates were left in 
the final model if the p-value was <0.10. Statistical testing was 
performed on SPSS software (IBM SPSS Statistics Version 24, 
IBM Corporation, Armonk, New York, USA). Use of center data 
for retrospective analysis has been reviewed and approved by 
the Institutional Review Board (Indiana University School of 
Medicine, study number 1011003619R005). The study protocol 
for this research conformed to the Declaration of Helsinki.
Results
There were 1830 liver transplants included in this analysis: 1737 
were DBD and 93 were DCD. There were 521 cases (28%) in 
which the liver donor experienced PPCA (mean 25 min, range 
1–120 min). Among 1737 DBD cases, 475 had PPCA (27%). This 
is less than among DCD cases, in which 46 of 93 had PPCA 
(49%). Among the 521 donors with PPCA, the arrest time was 
less than 20 min for 205 (39%), 20–39 min for 204 (39%), and 
40 min or more for 112 (22%). Reviewing the demographics of 
the organ donors, the PPCA donors were tended to be younger, 
non-white, and died primarily from hypoxic injury (generally 
related to drug overdose). There was no difference in sex or 
regional origin of the graft. Recipients were statistically similar, 
though the recipients of grafts from the PPCA donors were 
slightly older. Cold and warm ischemia times were both sta-
tistically lower for the PPCA grafts (Table 1).
Analysis of DCD cases demonstrates an expected increasing 
peak pre-procurement ALT level with increasing PPCA time 
(p<0.001). The peak donor bilirubin levels did not differ. Post-
transplant, the PPCA grafts had a lower peak and post-oper-
ative day 3 ALT level (p=0.01, p=0.15). They also had a lower 
peak total bilirubin level (p=0.01). When combining the 3 PPCA 
groups and comparing them to the non-PPCA group, the inci-
dence of early allograft dysfunction was lower for PPCA than 
for non-PPCA grafts (25% vs. 28%, p=0.22). There was no dif-
ference in hospital length of stay or in graft survival at 7 and 
30 days post-transplant. One-year graft survival was also sim-
ilar among all groups (Table 2).
Among the 93 DCD cases, there was a higher peak ALT level 
prior to donation, but not total bilirubin level, for PPCA patients 
(p=0.34, p=0.27). Post-transplant labs show no difference in 
peak and post-operative day 3 ALT, or in peak total bilirubin. 
There was no difference between the groups in early allograft 
dysfunction or length of hospital stay. There was a higher 
rate of early graft loss for the 2 PPCA groups (20–39 and 40 
or more min) (5% and 10%, p=0.16), and a lower 1-year graft 
survival for the 10 donors with more than 40-min PPCA time 
(70%, p=0.61), but none of these outcomes reached statistical 
significance (Table 3).
Cox regression analysis was used to assess 10-year graft sur-
vival. The median death-censored follow-up time was 66 
months. For DBD, the grafts from donors with no PPCA had 
slightly higher survival compared to all groups with PPCA, but 
this did not reach statistical significance (Figure 1A). For DCD, 
there was a markedly higher survival for donor grafts with no 
PPCA when compared to all PPCA patients grouped together; 
however, this difference was not statistically significant given 
the small numbers in this subgroup (Figure 1B).
Discussion
This study supports previous research suggesting that post-
transplant ischemia and reperfusion injury may be ame-
liorated by a pre-procurement ischemic event (ischemic 
preconditioning). In this analysis of 1737 non-DCD liver donors, 
post-transplant ALT and total bilirubin levels were lower for all 
lengths of PPCA compared to liver grafts with no PPCA, but this 
did not affect clinical outcomes, including early allograft dys-
function, length of hospital stay, and early and late graft sur-
vival. The results were less clear for the subset of DCD trans-
plants, although the smaller number in this group prevented 
a sufficiently-powered analysis. Use of liver grafts from care-
fully selected donors with PPCA appears to be a safe and ap-
propriate means of expanding the liver donor pool.
In this cohort there were 112 donors with over 40 min of docu-
mented arrest time, and this group had outcomes better than, 
or similar to, donors who had no PPCA. In assessing these 
donors, care must be taken to account for a variety of other 
factors, including donor age, graft steatosis, predicted cold and 
warm ischemia time, and recipient age, as well as model for 
end-stage liver disease score and biopsy results. Clearly, not all 
donors who have recovered from cardiac arrest will be accept-
able donors, but an important percentage should be pursued. 
On-site frozen-section biopsy is an important tool for use in 
assessing these grafts [29]. At our center, we transplant donor 
grafts with prolonged ischemia and elevated ALT levels as long 
as the biopsy demonstrates ischemic injury (necrosis) of less 
than 20%. An important clinical marker for liver function in 
the organ donor is the donor pH, as the liver has an important 
and active role in modulating body pH, along with the lungs 
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and kidneys. A patient for whom the pH cannot be corrected 
and with no clear source for acidosis identified may have ex-
tensive hepatic necrosis or poor physiologic function that is 
not fully represented by biochemical measures of liver injury.
Subgroup analysis of DCD liver grafts from PPCA donors 
supports previous research published by the group from 
Birmingham (UK), which analyzed 26 PPCA-DCD grafts [10]. 
Of 93 DCD liver grafts in our study, 46 had PPCA (49%). 
Early graft function in this group was equivalent to donors 
with no PPCA. Donors with PPCA time up to 40 min experi-
enced similar 1-year survival compared to non-PPCA donors. 
The PPCA-DCD group with more than 40 min of arrest time 
comprised only 10 patients. Of these, 1 graft was lost in the 
first week and 2 more were lost within the first year. These 
small numbers fail to adequately inform decision-making for 
this group. Alternatively, the fact that 7 of 10 DCD donors with 
PPCA time over 40 min achieved normal function at 1 year 
Overall
No donor out-
of-hospital 
cardiac arrest
Donor out-of-hospital cardiac arrest time
p-Value
<20 minutes 20–40 minutes >40 minutes
Overall 1830 1309 (72%) 205 (11%) 204 (11%) 112 (6%)
Donor
 Gender: Male 58% 58% 57% 56% 55% 0.93
 Race: White 82% 90% 86% 85% 85% 0.03
 Age (years)
  Median (range) 41 42 36 38 40 <0.001
 Donor cause of death <0.001
  Stroke 39% 48% 19% 13% 15%
  Trauma 36% 41% 39% 11% 11%
  Anoxia/other 25% 12% 42% 76% 75%
 Donation after cardiac death 5% 4% 8% 9% 9% <0.001
 Regional origin of graft
  Local 70% 71% 68% 66% 62% 0.22
Recipient
 MELD (median) 18 18 20 19 20 0.21
 Gender: Male 68% 68% 69% 70% 67% 0.90
 Race: White 89% 89% 86% 89% 88% 0.13
 Age (years)
  Median 55 54 57 56 57 0.03
 Body mass index
  Median 28.1 28.1 28.9 29.0 27.7 0.76
 Retransplant 4% 4% 3% 4% 4% 0.22
Transplant data
 Total ischemia time (median)
  Cold (hours) 6.2 6.4 6.0 6.0 6.0 <0.001
  Warm (minutes) 24 25 22 21 21 <0.001
Table 1.  Demographic data for 1830 liver transplant patients with comparison of patients in which the deceased donor did or did not 
experience out-of-hospital cardiac arrest prior to organ donation.
811
Mangus R.S. et al.: 
Impact of donor PPCA on clinical outcomes in liver transplantation
© Ann Transplant, 2018; 23: 808-814
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
 Overall
No donor 
 cardiopulmonary 
arrest
Donor cardiopulmonary arrest time
p- 
Value<20 minutes 20–39 minutes ³40 minutes
Number 1737 1262 (73%) 188 (11%) 185 (11%) 102 (6%)
Donor laboratory value (median)
 Peak alanine aminotransferase 47 38 86 142 211 <0.001
 Peak total bilirubin 0.8 0.8 0.9 0.8 0.7 0.14
Recipient laboratory values (median)
 Peak alanine aminotransferase 482 503 412 388 395 0.01
 Day 3 alanine aminotransferase 248 283 201 191 215 0.15
 Peak total bilirubin 5.0 5.3 4.6 4.3 4.1 0.01
Early allograft dysfunction* 27% 28% 25% 27% 22% 0.45
Length of hospital stay (days, median) 10 10 10 10 10 0.70
7-day graft loss 3% 3% 2% 2% 3% 0.82
30-day graft loss 5% 6% 5% 3% 6% 0.42
1-year graft survival 88% 88% 86% 92% 88% 0.31
Table 2.  For donation after brain death, a comparison of graft laboratory values and post-transplant function by donor pre-
procurement out-of-hospital cardiac arrest time.
* Early allograft dysfunction defined as AST or ALT greater than 1000u/L in first 7 days, day 7 total bilirubin ³10.0, or day 7 INR ³1.6.
 Overall
No donor 
 cardiopulmonary 
arrest
Donor cardiopulmonary arrest time
p- 
Value<20 minutes 20–39 minutes ³40 minutes
Number 93 47 (51%) 17 (18%) 19 (20%) 10 (11%)
Donor laboratory value (median)
 Peak alanine aminotransferase 102 65 131 121 195 0.34
 Peak total bilirubin 0.8 0.8 0.6 0.8 1.2 0.27
Recipient laboratory values (median)
 Peak alanine aminotransferase 972 1114 1151 677 1087 0.96
 Day 3 alanine aminotransferase 362 418 361 233 538 0.66
 Peak total bilirubin 6.6 7.3 7.6 6.4 4.6 0.48
Early allograft dysfunction* 51% 55% 53% 37% 50% 0.59
Length of hospital stay (days, median) 13 13 13 14 9 0.68
7-day graft loss 2% 0% 0% 5% 10% 0.16
30-day graft loss 2% 0% 0% 5% 10% 0.16
1-year graft survival 84% 87% 82% 84% 70% 0.61
Table 3.  For donation after cardiac death, a comparison of graft laboratory values and post-transplant function by donor pre-
procurement out-of-hospital cardiac arrest time.
* Early allograft dysfunction defined as AST or ALT greater than 1000u/L in first 7 days, day 7 total bilirubin ³10.0, or day 7 INR ³1.6.
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(and 50% survival at 10 years) is an important indication of 
the value of these donors.
The limitations of this study are similar to those seen in other 
studies of this type. Donor liver grafts with PPCA that were 
transplanted were likely different from non-PPCA donors. In the 
demographic assessment, the PPCA donors were younger and 
had slightly less cold and warm ischemia time, which may have 
affected outcomes. Steatosis was not assessed in this analysis, 
but high-risk steatotic grafts with PPCA may have been cate-
gorically excluded. Unfortunately, in this cohort, the denomi-
nator (number of PPCA grafts rejected for transplant) was not 
available. In other words, grafts with PPCA likely had to be per-
fect in other all other ways to be used for transplant. Such an 
unknown factor would bias results. Also, in this analysis, PPCA 
could not be confirmed by objective testing. Pre-hospital care 
providers may have limited skills in detecting low blood pres-
sure, and may inappropriately initiate chest compressions or 
the chest compressions may be inadequate to circulate blood 
sufficiently. An elevation of serum ALT after successful resus-
citation acts as a marker for true ischemic injury to the liver, 
and also correlates with the severity of injury. Our group has 
previously shown a correlation between elevated liver function 
tests and clinical outcomes, with elevations up to 2000 u/L 
having similar long-term outcomes [30]. Such an elevation of 
serum ALT may be a better marker for ischemic preconditioning 
compared to minutes of cardiac arrest time.
Conclusions
This study provides additional information in the ongoing 
expansion of the acceptable pool of liver donors. Further 
research will focus on identifying donors with PPCA who were 
rejected for transplant, to determine the ability to use those 
organs as well. Also, analysis of the reperfusion biopsies from 
donors with PPCA may lead to identification of signs of early 
injury that are reversible. Similar research in this population 
can easily be extended to other solid organs.
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Figure 1.  (A) Cox regression graft survival for 1737 donation after brain death liver transplants, with groups stratified by donor pre-
procurement cardiac arrest time (minutes). (B) Cox regression graft survival for 93 donations after cardiac death liver 
transplants, with groups stratified by donor pre-procurement cardiac arrest time (minutes).
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